fda semaglutide update Receives Approval for Treatment of MASH The FDA's Decision to Ban

GSTZ1-1 deficiency activates NRF2/IGF1R axis in HCC via accumulation of oncometabolite succinylacetone

A comparison of preferences for two GLP-1 productsliraglutide and exenatidefor the treatment of type 2 diabetes

Pharmaceutical GLP-1 receptor agonists work by directly binding to GLP-1 receptors throughout the body at sustained concentrations far beyond what natural production achieves

[1] Type 2 diabetes can lead to various complications, including heart disease, stroke, kidney disease, and blindness, so managing the disease is extremely important

CJC-1295 is modified (the version used in our clinic is CJC-1295 without DAC) to extend that signal, keeping the GHRH stimulus present long enough for a meaningful pulse of growth hormone to occur